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1 |  INTRODUCTION
Congenital nephrogenic diabetes insipidus (NDI) is a rare 
disease that is characterized by the excretion of abnormally 
large volumes of urine, due to the inability of the kidneys to 
concentrate urine in response to arginine vasopressin (AVP) 
(Sasaki, 2004; Wesche, Deen, & Knoers, 2012). Patients 
with congenital NDI typically present in infancy with severe 
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Abstract
Background: Congenital nephrogenic diabetes insipidus (NDI) is a rare condition 
characterized by severe polyuria, due to the inability of the kidneys to concentrate 
urine in response to arginine vasopressin (AVP). In the majority of the cases, the 
disease shows an X‐linked inherited pattern, although an autosomal recessive inher-
itance was also observed.
Methods: We report a patient with a severe NDI diagnosed during the neonatal pe-
riod. Because the patient was female without a family history of congenital NDI, her 
disease was thought to exhibit an autosomal recessive form.
Results: A full mutation analysis of AVP receptor 2 (AVPR2; MIM#300538) gene 
showed no mutations. However, direct Sanger sequencing of the aquaporin 2 (AQP2) 
revealed an apparently homozygous mutation at nucleotide position 
NM_000486.5:c.374C>T (p.Thr125Met) in exon 2. Further customized multiplex 
ligation‐dependent probe amplification (MLPA), single‐nucleotide polymorphism 
(SNP) array analysis, and long‐range polymerase chain reaction (PCR) followed by 
Sanger sequencing showed a heterozygous exonic deletion comprising exons 2, 3, 
and partially 4 of AQP2.
Conclusion: This is the first case of a compound heterozygote patient with a mis-
sense mutation involving NM_000486.5:exon2:c.374C>T (p.Thr125Met) and a 
gross deletion of at least exons 2, 3, and partially 4 on the AQP2 to present with a 
severe NDI phenotype.
K E Y W O R D S
aquaporin 2 gene, compound heterozygous mutation, exonic deletion, nephrogenic diabetes insipidus, p.
T125M mutation, polyuria, (SNP) array
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polyuria, polydipsia, and growth failure. The majority (90%) 
of inherited cases is caused by mutations in the AVP recep-
tor 2 (AVPR2; MIM#300538) gene on chromosome Xq28 
(Sasaki, 2004; Wesche et al., 2012). This gene encodes the 
vasopressin receptor, type 2, also known as the V2 receptor, 
which belongs to the seven‐transmembrane‐domain G pro-
tein‐coupled receptor (GPCR) superfamily, and couples to 
Gs thus stimulating adenylate cyclase. However, about 10% 
of congenital NDI might be caused by aquaporin 2 (AQP2; 
MIM#107777) gene mutations, and most of them are auto-
somal recessive forms of inheritance (Sasaki, 2004; Sasaki, 
Chiga, Kikuchi, Rai, & Uchida, 2013; Wesche et al., 2012). 
In fact, the genetic causes of NDI vary among different eth-
nic groups (Sasaki, 2004; Sasaki et al., 2013; Wesche et al., 
2012). The human AQP2 is located on chromosome 12q13.12 
(Sasaki, 2004). This gene has four exons and three introns and 
encodes a 271‐amino acid protein with six transmembrane 
domains (Wesche et al., 2012). AQP2 is expressed predomi-
nantly at the apical region of the principal cells of collecting 
duct and the inner medullary collecting duct cells (Nielsen 
et al., 1995). In these cells, the vasopressin increases the os-
motic water permeability apical membrane by triggering exo-
cytosis of AQP2‐containing vesicles (Nielsen et al., 1995). 
Here, using several molecular approaches, we report a female 
proband with NDI to be found a compound heterozygote for a 
first time reported AQP2 exonic deletion (comprising at least 
exons 2, 3, and 4, partially), and also carrying a missense 
mutation, previously described in the undeleted allele.
2 |  METHODS
2.1 | Case presentation
The patient, currently 32‐year‐old, was the second child of a 
healthy nonconsanguineous couple. Family history was neg-
ative for NDI disease. The pregnancy was uneventful, and 
the child was delivered to term by vaginal via. Birth weight 
was 3,300 g. Her elder brother was healthy. She was admit-
ted to the hospital at the age of 4 weeks presenting symp-
toms of dehydration, polyuria, polydipsia, vomiting, fever of 
unknown origin, and weight loss. Laboratory data showed 
hypernatremia, high serum osmolality, and low urine osmo-
lality. Thus, the diagnosis of NDI was suspected. Treatment 
with adequate hydration and hydrochlorothiazide initiated 
2 days later leads to ion levels normalized, as well as blood 
urea and serum creatinine levels. Clinical diagnosis was con-
firmed by dDAVP infusion test without elevation of urine os-
molality (before 58 mOsmol/kg H2O and after 69 mOsmol/
kg H2O). Thereafter, she developed similar episodes of vom-
iting and febrile illness requiring hospitalization five more 
times up to the last episode, produced in 1998. At the age of 
22 years was remitted to our out‐patient clinic for a complete 
clinical evaluation. Brain magnetic resonance imaging and 
ultrasonographic examination of both kidneys revealed no 
abnormality at all. Currently (with 32 years old), her height 
is 158 cm and her weight 48 kg. She remains with stable 
polyuria of about 6–6.5 L/day and maintains normal serum 
levels of sodium, potassium, calcium, bicarbonate, and phos-
phate, with hypocalciuria (urine calcium/creatinine, 0.1 mg/
mg), a serum level of magnesium of 1.6 mg/dl with a frac-
tional urinary excretion of magnesium of 13%, a blood urea 
of 23 mg/dl, a serum creatinine of 0.75 mg/dl, and MDRD of 
109 ml/min/1.73 m2. Urine osmolality and plasma osmolality 
are 138 and 285 mOsm/Kg H2O, respectively. The treatment 
currently is with hydrochlorothiazide (1.5 mg/kg per day), 
amiloride (0.15 mg/kg per day), indomethacin (100 mg per 
day), potassium chloride (40 mmol per day), magnesium hy-
droxide (308 mg per day), and ranitidine (300 mg per day). 
Recently, she is also under treatment with fluvastatin (40 mg 
daily).
2.2 | Molecular analysis
2.2.1 | Sanger direct sequencing for 
AVPR2 and AQP2
Genomic DNA was extracted from peripheral blood lym-
phocytes with Gentra Puregene Blood Kit (QIAGEN GmbH, 
Hilden, Germany). Genomic DNA mutation screening of 
the AVPR2 and AQP2 genes was performed for our proband 
and her parents. New primers were designed to amplify all 
exons and flanking intronic regions of both genes, so that all 
fragments could be amplified by polymerase chain reaction 
(PCR) simultaneously. After amplification, the PCR products 
were purified using a PCR purification kit (GE Healthcare) 
and then sequenced with BigDye 3.1 (Applied Biosystems; 
life technologies). The sequences were analyzed with an ABI 
PRISM 37130xl DNA Analyzer (Applied Biosystems Life 
Technologies, USA).
2.2.2 | Short tandem repeats (STR) 
microsatellites analyses
A panel of eight microsatellites corresponding to chromo-
some 12 was evaluated in the propositus and her parents 
(the complete list of STRs under request). Sequences of the 
primers were obtained from the NCBI public database (http://
www.ncbi.nlm.nih.gov/sites/entrez). PCR and capillary elec-
trophoresis conditions were adapted from universal labora-
tory protocols.
2.2.3 | Multiplex ligation‐dependent probe 
amplification (MLPA) analysis
A customized MLPA was designed by us. Briefly, four 
synthetic DNA probes within AQP2 plus four reference 
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probes were designed, complementary to the regions we 
wanted to test. Targets were located in the 5′ upstream re-
gion and intronic regions 1, 2, and 3 of the gene, whereas 
reference probes hybridized to other chromosomal regions 
outside of 12q13.12, expected to be normal. Following am-
plification and fragment separation in an automated DNA 
sequence analyzer (ABI3130XL; Life Tech. Grand Island, 
NY, USA). Data analysis was made against up to 5 con-
trol samples using than in‐house Excel spreadsheet. Target 
peak heights were normalized against the sum of all control 
peak heights, using this value to express the AQP2 dos-
age as a patient sample/control sample ratio (1 = normal, 
0.5 = deletion, 1.5 = duplication).
2.2.4 | High‐density (SNP) arrays
Extracted DNAs were quantified using PicoGreen 
(Invitrogen Corporation, Carlsbad, CA). A genome‐wide 
scan of 850,00 tag SNPs was conducted on the proband, 
using the Illumina CytoSNP‐850k BeadChip accord-
ing to the manufacturer's specifications (Illumina, San 
Diego, CA). GenCall scores < 0.15 at any locus were con-
sidered "no calls." Image data were analyzed using the 
Chromosome Viewer tool contained in Genome Studio 
(Illumina, San Diego, CA). The metric used was the log R 
ratio which is the log (base 2) ratio of the observed normal-
ized R value for a SNP divided by the expected normalized 
F I G U R E  1  (a) Left panel: sequence electropherograms of AQP2 exon 2, showing the nucleotide change NM_000486.5:exon2:c.374C>T 
(p.Thr125Met) (red arrow) in the proband (upper panel), her father (middle panel), and the wild‐type sequence in her mother (bottom panel). Right 
panel: MLPA analysis showing AQP2 dosage of the proband (up), her father (middle), and her mother (down). C: control sample; In: intron; UTR: 
untranslated region. (b) (SNP) array analysis in the proband using CytoSNP 850K (Illumina, USA). Allele frequency and log R ratio of the SNPs 
within AQP2 in chromosome 12 have shown. (c) Delimitation of breakpoints for deletion at AQP2 region using specific primers (available upon 
request), long‐range PCR, and Sanger sequencing in an ABI 3070 XL. (d) Mutation pedigree in the family. (e) Predicted G‐quadruplex sequences 
in the patient included herein using QGRS software. Analysis was performed within 100 bp at the breakpoint site. (f) Overview of sequence motifs 
at the delineated breakpoints. Whole junction fragment analysis was performed with BLASTN application, University of California Santa Cruz 
Genome Browser, Sequencher DNA Sequence Analysis Software, and RepeatMasker application
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R value (under manufacturer`s specifications). In addi-
tion, an allele frequency analysis was applied for all SNPs. 
All genomic positions were based upon NCBI Build 37 
(dbSNP version 130).
2.2.5 | Detection of breakpoints and 
junction fragment analysis with long‐range 
PCR and sanger sequencing
To precisely determine the sequence at the breakpoints of the 
exonic AQP2 deletion, we designed a different set of prim-
ers (available upon request) located immediately outside the 
deleted region, according to our (SNP) array results. The 
PCRs were performed according to previous described meth-
ods. Sequence chromatograms were aligned and analyzed by 
Sequencher version‐4.8 (Gene Code, Applied Biosciences; 
http//www.genecodes.com). Whole junction fragments were 
analyzed with BLASTN application (BLASTN applica-
tion; http//www.ncbi.nlm.nih.gob/BLAST), University of 
California Santa Cruz Genome Browser (https://genome.
ucsc.edu/), and RepeatMasker application; http://www.re-
peatmasker.org/).
3 |  RESULTS
After obtaining written informed consent, punctual muta-
tion analysis of the patient and her parents was initially per-
formed by PCR amplification and direct DNA sequencing 
of the AVPR2 using a set of newly designed primers (avail-
able upon request). Full mutational analysis of the AVPR2 
demonstrated no mutations in the proband neither her par-
ents. However, analysis of the AQP2 (primers were available 
upon request) revealed an, apparently, homozygous mutation 
NM_000486.5:exon2:c.374C>T (p.Thr125Met). Parental 
analysis revealed that her father was heterozygous for the 
same missense mutation (Figure 1a, middle left panel), 
whereas no punctual mutation in AQP2 was found in her 
mother (Figure 1a, bottom left panel). This discordant allelic 
segregation in our proband could be explained by either an 
AQP2 deletion in the other allele (inherited from her mother), 
causing a loss of heterozygosity and an apparently homozy-
gous mutation in exon 2, or consequence of an uniparental 
disomy (UPD) of chromosome 12. A segregation study of 
eight microsatellite markers flanking AQP2 ruled out UPD 
at this chromosomal region (data not shown), as well as the 
(SNP) array in the proband after all (Figure 1b).
A customized MLPA panel was designed by us to test 
a putative AQP2 deletion in the other allele (see Methods). 
Results confirmed a chromosomal deletion in the patient 
and her mother, spanning minimally from intron 1 to intron 
3 and thus affecting at least, exons 2 and 3 of AQP2 (Figure 
1a, top and bottom right panels). The expected size for the 
deletion was estimated of at least 1.27 kb (genomic coordi-
nates; [hg19]: 50347770_50349044), and no estimated distal 
breakpoint can be done using MLPA. Additional (SNP) array 
analysis (cytoSNP850K, Illumina) in the proband established 
the size of deletion between 1,983 and 5,092 kb (see Figure 
1b; genomic coordinates; [hg19]: 50345206_50350298 and 
[hg19]: 50347938_50349021, respectively) within exon 2 to 
exon 4, partially. In addition, based on (SNP) array genomic 
coordinates, we designed primers to determine deletion 
breakpoints by a long‐range PCR, which is showed in Figure 
1c, establishing a deletion of 3.6 kb long. The brother of the 
patient (who has no renal affectation) did not undergo any 
molecular genetic analysis yet (Figure 1d).
3.1 | Use of chemical chaperones
Finally, during the last 12 months, she was under treatment 
with fluvastatin (40 mg/daily), which was not accompanied 
by a reduction of diuresis or an increase of urine osmolality.
4 |  DISCUSSION
AQP2, located at the luminal side of the collecting duct 
principal cells, is a water channel responsible for the final 
concentration of urine in response to AVP. Lack of func-
tion, often occurring through mistargeting of mutated pro-
teins, induces NDI, a condition characterized by large urinary 
volumes. Autosomal recessive NDI is a rare disease usu-
ally seen in patient with consanguineous parents (Bichet et 
al., 2012; Sasaki, 2004; Wesche et al., 2012). Since most 
AQP2‐related NDI are found to be recessive hereditary traits 
(Robben, Knoers, & Deen, 2006), heterozygotes bearing one 
wild‐type form of the protein are usually nonsymptomatic 
as two defective alleles are required to induce the disease. 
We report on a case of severe autosomal recessive NDI in 
a female patient with nonconsanguineous parents. Severe 
polyuria and polydipsia began soon after birth, and these 
findings in association with the patient's sex and the failure 
of dDAVP to relieve symptoms suggested that NDI could 
be caused by mutation(s) in the AQP2. In fact, we found a 
compound heterozygous mutation, NM_000486.5:c.374C>T 
(p.Thr125Met) of exon 2, which have been previously de-
scribed (Goji et al., 1998; Kuwahara, 1998; Kuwahara et al., 
2001; Marr, Bichet, Hoefs et al., 2002; Shinbo et al., 1999; 
Tsutsumi et al., 2009) and a deletion of at least exons 2, 3, 
and partially 4, which has not been described previously, in 
the AQP2 of our proband (3.6 kb long; Figures 1c and 2a). 
Haploinsufficiency score for AQP2 was <50% (43.8%, which 
means medium to high score of haploinsufficiency) (Huang, 
Lee, Marcotte, & Hurles, 2010). The AQP2 point mutation 
NM_000486.5:exon2:c.374C>T (p.Thr125Met) was inher-
ited from the asymptomatic father, while her mother carried 
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the exonic deletion, and neither showed any manifestations 
of NDI disease. In fact, clinical ion level analysis either in 
blood or in urine, as well as the osmolality monitoring in both 
parents revealed normal values without suspicious NDI dis-
ease. In addition, her elder brother had no NDI either. Thus, 
in this family the two combined mutations (Figure 1d) seem 
to be disease causative for a severe clinical form of NDI.
So far, various mutations in the AQP2 have been demon-
strated in both the autosomal recessive and dominant forms 
of NDI, in which mutations are distributed throughout the 
gene without any apparently mutation hot spot (Moon et 
al., 2009; Sasaki, 2004; Sasaki et al., 2013; Wesche et al., 
2012). Currently, 54 mutations known to give rise to autoso-
mal recessive NDI (Milano, Carmosino, Gerbino, Svelto, & 
Procino, 2017; Moeller, Rittig, & Fenton, 2013; Wesche et 
al., 2012). Thus, 46 missense/nonsense, four splicing muta-
tions, and one small insertion were reported. In addition, a mi-
nority of cases (up to seven), NDI results from small genomic 
deletions in the AQP2 (Bichet et al., 2012; García Castaño 
et al., 2015; Lieburg et al., 1994; Marr, Bichet, Lonergan et 
al., 2002; Moeller et al., 2013; Ohzeki, Igarashi, & Okamoto, 
1984; Tajima, Okuhara, Satoh, Nakae, & Fujieda, 2003). 
However, no gross deletion was found at this time so ever: 
a deletion of G at nucleotide 721 (721delG), a deletion of 
10 nucleotides starting at nucleotide 763 (763_772del), 
and a deletion of 7 nucleotides starting at nucleotide 812 
(812_818del) (Bichet et al., 2012; Kuwahara et al., 2001; 
Sohara et al., 2006). In addition, a study by Park, Baik, 
Cheong, and Kang, (2014) described a young Korean male 
with a compound heterozygous mutations located in exon 
1. One of the mutations was a frameshift mutation result-
ing from a deletion NM_000486.5:c.127_128delCA (p.Gl-
n43Aspfs*63). Cen, Nie, Duan, and Gu, (2015) reported two 
Chinese male individuals with inherited NDI. Proband 1 pre-
sented the previously reported heterozygous frameshift mu-
tation c.127_128delCA (p.Gln43Aspfs*63) inherited from 
F I G U R E  2  Schematic representation of mutations found in the proband within AQP2 using different technologies. (a) Structure of aquaporin 
2 embedded in the cell membrane reporting the protein mutations by deletion that cause nephrogenic diabetes insipidus (in blue). (b) The location 
of the identified deletion of at least exons 2, 3, and 4 is marked in red in the AQP2 protein
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the mother and a novel frameshift mutation c.501_502insC 
(p.Val168Argfs*30), inherited from the father, suggesting 
that the patient with truncated AQP2 protein presented with 
much more severe NDI manifestations.
The relationships between AQP2 mutations and its func-
tion have not been completely elucidated. However, misfold-
ing of the protein and retention in the endoplasmic reticulum 
have been reported in most AQP2 mutations (Cheong et al., 
2005), except for those of NM_000486.5:exon2:c.374C>T 
(p.Thr125Met), in which a disrupted water channel func-
tion is indicated (Goji et al., 1998; Marr, Bichet, Hoefs et 
al., 2002). To date, this missense mutation in the AQP2 has 
been described in several cases, the majority in Japanese 
families (Goji et al., 1998; Kuwahara, 1998; Kuwahara 
et al., 2001; Marr, Bichet, Hoefs et al., 2002; Tsutsumi et 
al., 2009), yielding a protein to be partially functional 
water channel (retained 25% of the single‐channel per-
meability) (Marr, Bichet, Hoefs et al., 2002). Moreover, 
NM_000486.5:exon2:c.374C>T (p.Thr125Met) mutation in 
the AQP2 has been also reported in several cases of NDI that 
were compound heterozygotes and were severely affected 
(Boussemart, Nsota, Martin‐Coignard, & Champion, 2009; 
Goji et al., 1998; Iolascon et al., 2007; Kuwahara, 1998; 
Leduc‐Nadeau et al., 2010; Lieburg et al., 1994; Tsutsumi et 
al., 2009), as the case described herein. These findings sug-
gest that in these cases the resulted truncated protein cannot 
exert its proper water channel function. As far as we know, a 
compound heterozygous for a punctual mutation and a gross 
deletion has not been reported to date. It is noteworthy the 
two mutations may produce very different effects on AQP2 
protein, a loss of channel function in the case of this mis-
sense mutation, and a severely altered AQP2 structure in the 
case of deletion. By analogy with other autosomal recessive 
disorders, one can predict that the combination of mutations 
presented in each allele may also play a role in the phenotype 
variability and severity of NDI. On the other hand, 7 small 
deletions have been previously found in affected with severe 
features of NDI disease (Bichet et al., 2012; Sasaki et al., 
2013). We described herein a novel exonic deletion (includ-
ing exons 2, 3, and partially 4) as a recessive trait in a patient 
showing a severe phenotype of NDI. This new deletion is 
within a preserved region of AQP2 that comprises several 
transmembrane domains of the protein, which are highly 
conserved among species (Sasaki et al., 2013). Deletions 
affecting exon 1 and other small deletions placed in the C‐
terminus of AQP2 (all of this with a dominant inheritance) 
were also associated with a more severe form of the disease 
than mutations in other parts of the gene (Kuwahara et al., 
2001; Sasaki et al., 2013; Sohara et al., 2006). Interestingly, 
the gross deletion described herein (affecting more than half 
of the protein, including C‐terminus, with an intact exon1) 
may also have a severe clinical phenotype and supports a 
critical role of the C‐terminus of the AQP2 in the functional 
trafficking of this protein. However, it did not show a domi-
nant inheritance, because of the strict monitoring of ion lev-
els in the carrier asymptomatic mother.
We characterized the breakpoints in the deletion by using 
the PCR mapping and junction fragment sequencing, followed 
by Bio‐informatic analysis in both breakpoints through several 
web tools, showing that those lay next to highly homologous re-
petitive sequences of two SINE elements (MIR type), but they 
did not mediate the rearrangements directly. According to the 
UCSC Genome Browser, the region deleted was not flanked 
by segmental duplications, although repeat element analysis 
demonstrated that deleted region was flanked by 2 bp (GG) 
stretch of identical sequence (Figure 1c) that may point out to a 
nonreplicative mechanism of formation, such as is nonhomolo-
gous end joining (NHEJ) (Lieber, 2008). In addition, it also re-
vealed several repeat and genomic architectural elements, such 
as palindromic DNA or stem‐loop structures within the deleted 
breakpoints that may modulate this nonrecurrent genomic rear-
rangement (Figure 1e–f). Searching for more than 20 specific 
sequence motifs (involved in DNA rearrangements elsewhere) 
in the 50 bp centered on the breakpoints led to the identification 
of a total of three consensus patterns (Figure 1f); among them, 
an immunoglobulin class switch repeat is found. The presence 
of this switch region motif, such as in several large AVPR2 de-
letions (Vargas‐Poussou et al., 1997), is therefore consistent 
with an involvement of these sequences in promoting these re-
arrangements. Finally, the deletion may also create a possible 
deletion hot spot at the breakpoints (Figure 1f), and moreover, 
a predicted G‐quadruplex sequence “GAATGGAATGGGG” 
was also found at 5′end of the deletion (Figure 1e).
Our patient was diagnosed with NDI on the basis of typical 
neonatal manifestations. Therapeutically, she received treat-
ment with hydrochlorothiazide, amiloride, and indometha-
cin (Anesi, Gemmis, Galla, & Hladnik, 2012; Bichet et al., 
2012; Olesen, Rutzler, Moeller, Praetorius, & Fenton, 2011; 
Wesche et al., 2012). Moreover, she received potassium, 
magnesium, and ranitidine. Despite which, she maintained 
polyuria of about 6 L/day. Indeed, this patient had a severe 
form of NDI. Recently, chemical chaperones have been tested 
to correct aberrant folding of AQP2 in autosomal recessive 
NDI (Moeller et al., 2013). Based on this, we analyzed the 
effect of treatment with fluvastatin during 12 months with-
out significant changes in urine excretion of water, sodium, 
potassium, and chloride. Therefore, although a possible ther-
apeutic approach to rescue the plasma membrane expression 
of functional misfolded mutant proteins is the use of chemi-
cal chaperones to promote escape from the endoplasmic re-
ticulum, for AQP2 mutations caused by deletions, insertions, 
splicing, or other complex rearrangements, it is impossible to 
consider this therapeutic option (Moeller et al., 2013).
In summary, this is the first case of NDI due to a com-
pound heterozygous mutation; a novel exonic deletion 
within at least exons 2, 3, and 4 (for a segment of 3.62 kb) 
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of AQP2, and a previously reported point mutation 
NM_000486.5:exon2:c.374C>T (p.Thr125Met). This study 
provides significant evidence that the interaction of both 
mutations is likely to be responsible for the severity of NDI 
symptoms in this female patient. It also emphasizes that the 
restriction of the identification of a single genetic defect can 
be misleading. The presence of additional gene mutations 
should be considered, especially if there is familial discor-
dant allelic segregation. In addition, this novel exonic dele-
tion as a recessive trait increases the spectrum type of the 
mutations affecting AQP2.
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